isoorientin / MMP Cancer Research Results

Isoorientin is specifically luteolin-6-C-glucoside

Isoorientin — a naturally occurring flavone C-glycoside, specifically luteolin-6-C-glucoside, also known as homoorientin. It is a dietary/plant polyphenol rather than an approved drug and occurs in multiple medicinal and food plants. Isoorientin is structurally related to orientin, but differs in the position of C-glucosylation. Its anticancer pharmacology is dominated by redox-dependent mitochondrial apoptosis and suppression of pro-survival signaling, while in non-cancer inflammatory and neurological models it generally behaves as an antioxidant and anti-inflammatory GSK3β/NF-κB modulator. This context-dependent redox behavior is important when interpreting apparently opposite ROS effects.
-buckwheat sprouts contain orientin, isoorientin, vitexin, isovitexin, and rutin

Primary mechanisms (ranked):

1. ROS-dependent mitochondrial apoptosis in cancer cells, with mitochondrial membrane-potential loss, cytochrome-c release, Bax/Bcl-2 shift and caspase activation.
2. PI3K/Akt survival-pathway suppression, contributing to apoptosis and reduced proliferation.
3. MAPK/STAT3/NF-κB modulation, typically with ↑ JNK/p38 and ↓ ERK, STAT3 and NF-κB signaling in susceptible cancer models.
4. Wnt/β-catenin/STAT3 suppression, reducing cancer stem-cell characteristics, epithelial-mesenchymal transition, invasion and tumorigenicity.
5. AMPK activation, associated with reduced proliferation, invasiveness, EMT-associated signaling and VEGF secretion in pancreatic cancer models.
6. Cell-cycle arrest, commonly G2/M in lung and gastric cancer models, involving ↓ cyclins/CDKs and ↑ p21/p27.
7. Autophagy induction accompanying apoptosis in selected models, particularly HepG2 cells, through ROS-, PI3K/Akt-, JNK-, p38- and p53-linked signaling.
8. Anti-inflammatory GSK3β inhibition with secondary NRF2/HO-1 activation in non-cancer cells; this is more relevant to neuroprotection and inflammatory disease than to the primary anticancer mechanism.

Bioavailability / PK relevance: Oral systemic exposure is low. In rats, absolute oral bioavailability was approximately 9%, with low circulating parent isoorientin after a 150 mg/kg oral dose and substantially greater formation of sulfated metabolite. Low aqueous solubility and extensive first-pass metabolism are important translational constraints. Reported intravenous terminal half-life in rats is approximately 1.7–2.1 hours.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 20–160 µM isoorientin, while oral administration produces low circulating parent-compound exposure. These concentrations therefore commonly exceed plausibly achievable systemic free-isoorientin concentrations after conventional oral dosing. Local gastrointestinal exposure, metabolites, high-dose experimental administration and specialized delivery systems may not follow this limitation to the same degree.

Clinical evidence status: Preclinical. Anticancer activity is supported by multiple cell studies and a small number of animal/xenograft studies, including oral squamous-cell carcinoma models. A 2026 systematic review identified 12 eligible anticancer studies but no established human oncology efficacy. Isoorientin is not an approved anticancer drug and there is no established therapeutic human cancer dose.

Isoorientin Cancer Mechanisms

TSF legend: P: 0–30 min    R: 30 min–3 hr    G: >3 hr

Isoorientin and Alzheimer’s disease — Isoorientin has meaningful preclinical AD relevance centered on inhibition of GSK3β and suppression of neuroinflammation. In APP/PS1 mice, chronic oral administration reduced GSK3β overactivation, tau hyperphosphorylation, amyloid-β deposition and microglial inflammation while improving long-term potentiation and spatial memory. Cell studies additionally show suppression of Aβ-induced ROS, NF-κB, iNOS, COX-2 and inflammatory cytokines. This evidence remains preclinical; no established human AD efficacy or therapeutic dose has been demonstrated.

Primary mechanisms (ranked):

1. GSK3β inhibition, reducing pathological tau phosphorylation and influencing downstream inflammatory and redox signaling.
2. Reduction of amyloid-β-associated pathology and Aβ-induced microglial activation.
3. NF-κB suppression with reduced TNF-α, IL-6, iNOS and COX-2.
4. Secondary NRF2/HO-1 activation and antioxidant protection in neural and microglial cells.
5. Protection of synaptic plasticity and cognitive function in animal models.

Clinical evidence status: Preclinical. Evidence includes cellular models and APP/PS1 transgenic mice, but there is no established clinical efficacy in human Alzheimer’s disease.

Isoorientin Alzheimer’s Mechanisms